1. Analyst View 2. Research Methodology 3. Antibody Drug Conjugate (ADC) - An Introduction 4. Global Antibody Drug Conjugates Market Outlook to 2023 5. Commercialized Antibody Drug Conjugates 5.1 ADCETRIS 5.2 Kadcyla 5.3 Mylotarg 5.4 Besponsa 6. Antibody Drug Conjugates Pipeline Analysis 6.1 By Companies 6.1.1 By Clinical Phase 6.1.2 By Indication 6.1.3 By Drug 6.1.4 By Type of Linker 6.1.5 By Technology 6.2 By Research Organizations 6.2.1 By Phase 6.2.2 By Indication 6.2.3 By Drug 6.2.4 By Type of Linker 6.2.5 By Technology 7. Drivers and Challenges 7.1 Drivers 7.1.1 Rising Global Cancer Epidemics 7.1.2 Advances in Linking Technologies Re-Instills Hope in ADC 7.1.3 Efforts towards Patent Protection to Drive ADC Market 7.1.4 Increasing Demand for Antibody Drug Conjugates 7.2 Challenges 7.2.1 Production Hurdles and Cost 7.2.2 Inadequacy of Experienced Manufacturers 7.2.3 Regulatory Challenges 8. Major Potential Antibody Drug Conjugates in Pipeline 8.1 By Companies 8.1.1 Glembatumumab Vedotin Therapeutics/CDX-011 - Celldex 8.1.2 Coltuximab Ravtansine/SAR3419 - ImmunoGen Inc. 8.1.3 Indatuximab Ravtansine/BT-062 – Biotest AG 8.1.4 Anti-PSMA ADC Therapeutic - Progenics Pharmaceuticals 8.1.5 Polatuzumab Vedotin/RG7596 - F. Hoffman-La Roche Ltd. 8.1.6 DMUC-4064A/RG7882 - F. Hoffman-La Roche Ltd. 8.1.7 Mirvetuximab Soravtansine/IMGN853 - ImmunoGen Inc. 8.2 By Research Organizations 8.2.1 SGM-101 - SurgiMab in Collaboration with Center for Human Drug Research, Netherlands 8.2.2 MOC31-PE - Creative Biolabs in Collaboration with Oslo University Hospital 9. Trends and Developments 9.1 ADC at the Forefront of Treating Hematological Malignancies 9.2 ADCs Proving Advantageous for Breast Cancer Patients 10. Strategic Alliances in the Global Antibody Drug Conjugates Industry 11. Competitive Assessment 11.1 Seattle Genetics, Inc. 11.2 F. Hoffman-La Roche Ltd. 11.3 Pfizer Inc. 11.4 ImmunoGen, Inc. 11.5 Bayer AG 11.6 Takeda Pharmaceutical Company Limited 11.7 Immunomedics, Inc. 11.8 Oxford BioTherapeutics 11.9 Concortis Biotherapeutics 11.10 NBE-Therapeutics

List of Tables: Table 5-1: Global - Incidence of Hodgkin Lymphoma, 2012, 2015, 2020, & 2025 Table 5-2: Global - Incidence of Non-Hodgkin Lymphoma, 2012, 2015, 2020, & 2025 Table 5-3: Major Ongoing Trials for ADCETRIS Table 5-4: Global - Incidence of Breast Cancer, 2012, 2015, 2020, & 2025 Table 5-5: Major Ongoing Trials for Kadcyla Table 5-6: Major Ongoing Trials for Mylotarg Table 5-7: Major Ongoing Trials for Besponsa Table 6-1: Global - ADC Pipeline of Companies Table 6-2: Global - ADC Pipeline of Research Organization Table 10-1: Major Strategic Alliances in the Global Antibody Drug Conjugates Industry (2014-2017) Table 11-1: Seattle Genetics, Inc. - Key Financials (Million US$), 2014-2016 Table 11-2: Seattle Genetics, Inc. - ADC Product Portfolio Table 11-3: Seattle Genetics, Inc. - ADCs in Pipeline Table 11-4: F. Hoffman-La Roche Ltd. - Key Financials (Million US$), 2014-2016 Table 11-5: F. Hoffman-La Roche Ltd. - ADC Product Portfolio Table 11-6: F. Hoffman-La Roche Ltd. - ADCs in Pipeline Table 11-7: Pfizer Inc. - Key Financials (Million US$), 2014-2016 Table 11-8: Pfizer Inc. - ADC Product Portfolio Table 11-9: Pfizer Inc. - ADCs in Pipeline Table 11-10: ImmunoGen, Inc. - Key Financials (Million US$), 2014-2016 Table 11-11: ImmunoGen, Inc. - ADCs in Pipeline Table 11-12: Bayer AG - Key Financials (Million US$), 2014-2016 Table 11-13: Bayer AG - ADCs in Pipeline Table 11-14: Takeda Pharmaceutical Company Limited - Key Financials (Million US$), 2014-2016 Table 11-15: Takeda Pharmaceutical Company Limited - ADCs in Pipeline Table 11-16: Immunomedics, Inc. - Key Financials (Million US$), 2015-2017 Table 11-17: Immunomedics, Inc. - ADCs in Pipeline Table 11-18: Oxford BioTherapeutics - ADCs in Pipeline Table 11-19: Concortis Biotherapeutics - ADCs in Pipeline Table 11-20: NBE-Therapeutics - ADCs in Pipeline List of Figures: Figure 3-1: ADC - Mechanism of Action Figure 4-1: Global - ADC Market (Billion US$), 2016, 2017 & 2023 Figure 5-1: Global - ADCETRIS Sales (Million US$), 2016 & 2017 Figure 5-2: Global - Kadcyla Sales (Million US$), 2016 & 2017 Figure 6-1: Global - ADCs Pipeline by Developing Organizations (%), 2017 Figure 6-2: Global - ADC Pipeline of Companies by Clinical Phase (%), 2017 Figure 6-3: Global - ADC Pipeline of Companies by Indication (%), 2017 Figure 6-4: Global - ADC Pipeline of Companies by Drug (%), 2017 Figure 6-5: Global - ADC Pipeline of Companies by Type of Linker (%), 2017 Figure 6-6: Global - ADC Pipeline of Companies by Technology (%), 2017 Figure 6-7: Global - ADC Pipeline of Research Organization by Clinical Phase (%), 2017 Figure 6-8: Global - ADC Pipeline of Research Organization by Indication (%), 2017 Figure 6-9: Global - ADC Pipeline of Research Organization by Drug (%), 2017 Figure 6-10: Global - ADC Pipeline of Research Organization by Type of Linker (%), 2017 Figure 6-11: Global - ADC Pipeline of Research Organization by Technology (%), 2017 Figure 11-1: F. Hoffman-La Roche Ltd. - Group Sales Breakup by Business Segments (%), 2016 Figure 11-2: Pfizer Inc. - Revenue Breakup by Business Segments (%), 2016 Figure 11-3: Pfizer Inc. - Revenue Breakup by Geography (%), 2016 Figure 11-4: Bayer AG - Sales Breakup by Business Segments (%), 2016 Figure 11-5: Bayer AG - Net Sales Breakup by Geography (%), 2016 Figure 11-6: Takeda Pharmaceutical Company Limited - Ethical Drugs Revenue Breakup by Geography (%), 2016 Figure 11-7: Immunomedics, Inc. - Revenue Breakup by Geography (%), 2017